This first phase III trial found that T‐DXd significantly improved PFS (9.9 vs. 5.1 months, HR = 0.50, 95% CI: 0.40–0.63, p < 0.001) and OS (23.9 vs. 17.5 months, HR = 0.64, 95% CI: 0.48–0.86, p = 0.0028) compared with chemotherapy in HER2‐low breast cancer patients [11]. The gene discussed is ERBB2; the disease is breast carcinoma.